Clinical Observation and Mechanism Study of Yunnan Baiyao in Different Stages of Diabetic Foot
Clinical Efficacy Observation and Mechanism Study of Yunnan Baiyao in Different Stages of Diabetic Foot
1 other identifier
interventional
100
1 country
1
Brief Summary
Yunnan Baiyao has been treating all kinds of wounds for 120 years, but the evidence of Evidence-based medicine that is truly convincing is insufficient, making its best application method unclear. This study explored the possible indications and use methods of Yunnan Baiyao in different stages of Diabetic foot, and obtained Evidence-based medicine evidence of clinical efficacy. Obtain the discarded tissues of Diabetic foot patients in the treatment and control groups of Yunnan Baiyao after wound debridement, conduct Transcriptome (BulkRNA seq) analysis and detection on the wound tissues, and analyze the related signal pathways and functional genes with significant differences, to help clarify the possible treatment targets of Yunnan Baiyao.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_4
Started Dec 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 25, 2023
CompletedFirst Posted
Study publicly available on registry
October 2, 2023
CompletedStudy Start
First participant enrolled
December 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2025
CompletedJune 25, 2024
June 1, 2024
1.1 years
September 25, 2023
June 21, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
2-week reduction rate of wound area
Difference in wound area before and after treatment
2 weeks
Study Arms (6)
control group 1
NO INTERVENTIONThe optimal clinical treatment scheme was used to treat the wound of progressive infection period patients for 2 weeks
powder group 1
EXPERIMENTALOn the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder was used to treat the wound of progressive infection period patients for 2 weeks
ointment group 1
EXPERIMENTALOn the basis of the optimal clinical treatment scheme, Yunnan Baiyao ointment was used to treat the wound of progressive infection period patients for 2 weeks
control group 2
NO INTERVENTIONThe optimal clinical treatment scheme was used to treat the wound of granulation period patients for 2 weeks
powder group 2
EXPERIMENTALOn the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder was used to treat the wound of granulation period patients for 2 weeks
ointment group 2
EXPERIMENTALOn the basis of the optimal clinical treatment scheme, Yunnan Baiyao ointment was used to treat the wound of granulation period patients for 2 weeks
Interventions
On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder or ointment was used to treat the wound for 2 weeks
Eligibility Criteria
You may qualify if:
- The age of the subjects is 18-80 years old;
- Diagnose diabetes according to WHO standards;
- Diagnosis of Diabetic foot;
- Confirmed as one of the stages of infection progression and granulation growth;
- Voluntarily participate in this study and sign an informed consent form.
You may not qualify if:
- Severe diseases such as acute myocardial infarction, heart failure, hepatitis, shock, and respiratory failure have not been corrected yet;
- Blood glucose is out of control, Glucose test#Fasting blood sugar\>15mmol /L, Glycated hemoglobin\>12%;
- There is active bleeding inside the wound, and routine basic treatment plans cannot be implemented;
- Serum albumin\<20g/L; Hemoglobin\<60g/L; Platelets\<50 × 109/L;
- Late stage subjects with malignant tumors;
- Active period of autoimmune diseases;
- Have a history of allergy to Yunnan Baiyao;
- The subject is unable to cooperate or has mental disorders;
- According to the judgment of the researcher, the subject has a clear reason that cannot be removed and affects wound healing, which is not suitable for this study or cannot comply with the requirements of this study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Peking University 3rd Hospital
Beijing, Beijing Municipality, 100191, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
September 25, 2023
First Posted
October 2, 2023
Study Start
December 1, 2023
Primary Completion
December 31, 2024
Study Completion
June 30, 2025
Last Updated
June 25, 2024
Record last verified: 2024-06
Data Sharing
- IPD Sharing
- Will not share